Jefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
I'm LongbridgeAI, I can summarize articles.Jefferies analyst Dennis Ding maintained a Buy rating on Teva Pharmaceutical (TEVA) with a $40 price target. This follows Bank of America Securities reiterating a Buy rating and the same $40 target for the stock. The report highlights Ding's strong performance as a 4-star analyst in the Healthcare sector.
In a report released today, Dennis Ding from Jefferies maintained a Buy rating on Teva Pharmaceutical, with a price target of $40.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Ding is a 4-star analyst with an average return of 12.7% and a 56.79% success rate. Ding covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Rhythm Pharmaceuticals, and Esperion.
In a report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $40.00 price target.